Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
5 studies found for:    16855634 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Not yet recruiting Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM)
Condition: Multiple Myeloma
Interventions: Drug: Pembrolizumab;   Drug: Lenalidomide;   Drug: Dexamethasone
2 Active, not recruiting Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma
Conditions: Multiple Myeloma in Relapse;   Refractory Multiple Myeloma;   Multiple Myeloma
Interventions: Drug: pomalidomide;   Drug: marizomib;   Drug: low-dose dexamethasone
3 Unknown  Study of Bendamustine, Lenalidomide and Low-dose Dexamethasone, for the Treatment of Patients With Relapsed Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Bendamustine;   Drug: Lenalidomide;   Drug: Dexamethasone
4 Completed
Has Results
Chloroquine in Combination With VELCADE and Cyclophosphamide for Relapsed and Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Velcade;   Drug: Cyclophosphamide;   Drug: Chloroquine
5 Unknown  Phase 1/2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: NPI-0052

Indicates status has not been verified in more than two years